5 research outputs found
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years
Recommended from our members
Abstract TP49: State of the Florida Stroke Coordinator: Hospital Inventory Survey Insights
Abstract only Background: Stroke coordinators (SC’s) are essential leaders of certified stroke centers which facilitate evidence-based stroke care, improving patient outcomes. Although this role has existed since the 1970’s, significant variability of responsibilities and staffing exists. Evidence based recommendations for SC staffing are scarce. Purpose: Utilizing the 2023 Florida Stroke Registry Hospital Inventory Survey (HIS), we describe current SC roles, responsibilities, and challenges in Florida. Methods: The Florida Stroke Registry (FSR), with state funding, tracks and measures Florida’s stroke center performance. FSR recently deployed the FSR HIS, a ten-part questionnaire examining various aspects of stroke program infrastructure. The survey was disseminated to 171 sites with 38 responses in the first wave. This is preliminary data from an HIS section focusing on SC staffing, workload, resources, and perceived challenges. Results: Responding sites all report a designated SC. Figure 1 describes SC’s Status (full vs. part-time), onboarding, and resources. Of note, only 35% of SC’s manage stroke full-time at a single site, SC turnover rate is high with 63% in the role <4 yrs. Stroke coordinators abstract for multiple databases, even with data abstractor support. In free-text responses, 58% (19/33) of SC’s cited lack of time and/or corporate structure for adequate program management as the biggest challenges in their role. Discussion: The preliminary study highlights significant challenges with high SC turnover, heavy workloads, and insufficient support. Stroke programs lack clear recommendations from certifying bodies for program personnel based on program volume. Future directions of FSR HIS include conducting additional dissemination waves, and an analysis of optimal stroke program staffing by cross-referencing certification level, patient volume and SC resources